Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker disease BEFREE Treatment with cisplatin/TRAIL also inhibited the expression of EGFR, p63, survivin, Bcl-2, and Bcl-xL in TNBC cells. 21252285 2011
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker disease BEFREE These findings indicate that MUC1-C is a target for the treatment of TNBCs unresponsive to agents that inhibit anti-apoptotic members of the BCL-2 family. 29760958 2018
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker disease BEFREE In vitro studies showed that treatment of triple negative breast cancer (TNBC) MDA-MB-231 cells with Se-PFPs (1) inhibited cell growth dose-dependently by arresting cells at G2 phase via inhibiting CDC25C-CyclinB1/CDC2 pathway; (2) caused apoptosis associated with increased p53, Bax, Puma and Noxa, decreased Bcl2, increased Bax/Bcl2 ratio and increased activities of caspases 3/9, suggesting its effect on p53-mediated cytochrome c-caspase pathway. 27865619 2016
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker disease BEFREE Therefore, adjunct of ABT-737 to docetaxel might be a new therapeutic option to overcome docetaxel resistance of TNBCs overexpressing Bcl-2. 30402442 2018
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker disease BEFREE Treatment with a Bcl-xL and Bcl-2 peptide had only a moderate effect on any of the TNBC cell lines, however, co-dosing an Mcl-1-selective peptide with a peptide that inhibits Bcl-xL and Bcl-2 was effective in each line tested. 26045046 2015
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker disease BEFREE Treatment with a combination of the Bcl-2 inhibitor ABT-199 and DR synergistically decreased the viability of the TNBC cell lines MDA-MB-231 and BT-549. 29876007 2018
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker disease BEFREE TNBC/Bcl2- patients appear to benefit from ATC-CT, whereas Bcl2+ TNBC seems to be resistant to ATC-CT and may benefit from a trial of different type of chemotherapy with/without novel-targeted agents. 23908177 2013
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker disease BEFREE Our findings provide evidence that DR_MOMP predicts responses of TNBC cells to genotoxic therapy, and can aid in the choice of the optimal BCL2 protein antagonist for combination treatments of resistant cells. 29352235 2018
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker disease BEFREE MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors. 27217294 2016
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker disease BEFREE Our data established that APS intervenes with TNBC cell invasion, proliferation, and apoptosis <i>via</i> the PIK3CG/AKT/BCL2 pathway and could thus offer a promising therapeutic strategy for TNBC. 31680955 2019
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 Biomarker disease BEFREE Here, we present genetic and pharmacologic evidence that the anti-apoptotic molecules BclxL and Bcl-2 and the pro-apoptotic factors BAD and BID cooperate to promote migration of TNBC cells stimulated with cl-CD95L. 27367565 2016
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression disease BEFREE We and others show, that low BCL2 expression was associated with good outcome of TNBC patients treated with both adjuvant and neoadjuvant anthracycline-based chemotherapy. 25374001 2014
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression disease BEFREE Specifically, we developed LbL-NS to deliver the tumor suppressor miR-34a into triple-negative breast cancer (TNBC) cells, and demonstrate that these constructs can safely and effectively regulate the expression of SIRT1 and Bcl-2, two known targets of miR-34a, to decrease cell proliferation. 30555597 2018
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression disease BEFREE The aim of the present study was to evaluate Bcl-2 antigen expression in luminal A and triple-negative breast cancer. 28801774 2017
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression disease BEFREE Elevated expression of Bcl-2 was an independent prognostic factor for poorer OS in TNBC and as such a significant marker for tumor aggressiveness. 28777433 2018
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression disease BEFREE These findings demonstrate that activation of STAT3 and Bcl-2 and reduction of ROS contribute to the development of radioresistance in TNBC, and niclosamide acts as a potent radiosensitizer via inhibiting STAT3 and Bcl-2 and increasing ROS generation in TNBC cells and xenograft tumors. 29855616 2018
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression disease BEFREE Women with triple-negative breast cancer treated with neoadjuvant chemotherapy between 2002 and 2012 were retrospectively analyzed for their expression of NF-κB/p65, Bcl2 and Ki67 by immunohistochemistry in pre- and post-treatment specimens. 26494004 2016
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression disease BEFREE Among recent alternative approaches being proposed, small interfering RNA (siRNA) gene therapy can potently suppress Bcl-2 proto-oncogene and p-glycoprotein gene expression, the most important chemotherapy resistance inducers in TNBC. 28624192 2017
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression disease BEFREE High levels of BCL2 expression predicted poor OS in basal-like (BL) TNBC patients treated with adjuvant anthracycline-based regimens (log-rank p = 0.033, hazard ratio (HR) 3.04, 95 % confidence interval (CI) 1.04-8.91) and a trend to poor RFS (log-rank p = 0.079) and poor BCSS (log-rank p = 0.056). 25616695 2015
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression disease BEFREE The combined effect of ionizing radiation and AMD3100 was determined in vitro by surviving fraction, cell cycle distribution, Bax and Bcl-2 expression, and apoptosis assays in a TNBC cell line (MDA-MB-231). 29317253 2018
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression disease BEFREE Ginsenoside Rg3 promotes cytotoxicity and apoptosis of Paclitaxel by inhibiting NF-κB signaling and modulating Bax/Bcl-2 expression on TNBC. 28231544 2017
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.100 AlteredExpression disease BEFREE Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy. 25179840 2014